CA3246335A1 - AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL - Google Patents
AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROLInfo
- Publication number
- CA3246335A1 CA3246335A1 CA3246335A CA3246335A CA3246335A1 CA 3246335 A1 CA3246335 A1 CA 3246335A1 CA 3246335 A CA3246335 A CA 3246335A CA 3246335 A CA3246335 A CA 3246335A CA 3246335 A1 CA3246335 A1 CA 3246335A1
- Authority
- CA
- Canada
- Prior art keywords
- sodium phosphate
- hydrocortisone
- pharmaceutical formulation
- monothioglycerol
- aqueous pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263321997P | 2022-03-21 | 2022-03-21 | |
| US63/321,997 | 2022-03-21 | ||
| US202263322934P | 2022-03-23 | 2022-03-23 | |
| US63/322,934 | 2022-03-23 | ||
| US202263387727P | 2022-12-16 | 2022-12-16 | |
| US63/387,727 | 2022-12-16 | ||
| PCT/US2023/064771 WO2023183807A1 (en) | 2022-03-21 | 2023-03-21 | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246335A1 true CA3246335A1 (en) | 2023-09-28 |
Family
ID=88102190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246335A Pending CA3246335A1 (en) | 2022-03-21 | 2023-03-21 | AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US12102643B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4496575A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509955A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3246335A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023183807A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4496575A4 (en) * | 2022-03-21 | 2026-04-01 | Antares Pharma Inc | AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2970944A (en) | 1958-04-04 | 1961-02-07 | Merck & Co Inc | Parenteral solutions of steroid phosphates stabilized with creatinines |
| IL34366A (en) * | 1969-05-07 | 1973-06-29 | Lepetit Spa | Stable aqueous 21-hydroxy steroid phosphate solutions |
| US5173488A (en) * | 1989-08-21 | 1992-12-22 | American Cyanamid Company | Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method |
| US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| WO2006079064A1 (en) | 2005-01-24 | 2006-07-27 | Antares Pharma, Inc. | Prefilled needle assisted jet injector |
| US8067433B2 (en) | 2005-11-09 | 2011-11-29 | Zalicus Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
| ES2548447T3 (es) | 2008-03-10 | 2015-10-16 | Antares Pharma, Inc. | Dispositivo de seguridad para inyector |
| US8579865B2 (en) | 2009-03-20 | 2013-11-12 | Antares Pharma, Inc. | Hazardous agent injection system |
| WO2014165142A1 (en) | 2013-03-13 | 2014-10-09 | Benjamin Newton | Multiple dosage injector with rotating screw dosage system |
| EP3189855B1 (en) * | 2016-01-11 | 2018-03-21 | Lamda Laboratories S.A. | Oral pharmaceutical solutions containing hydrocortisone sodium phosphate |
| FR3047904B1 (fr) | 2016-02-18 | 2018-03-23 | Crossject | Dispositif d’injection sans aiguille a membrane coulissante |
| FR3057775B1 (fr) * | 2016-10-26 | 2018-11-02 | Crossject | Solution pharmaceutique d’hydrocortisone pour dispositif d’injection |
| EP3787671A4 (en) | 2018-05-04 | 2022-06-15 | Ohio State Innovation Foundation | NON-PEPTIDE CELL-PENETRATING MOTIFS |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| AU2021345429A1 (en) * | 2020-09-21 | 2023-05-04 | Antares Pharma, Inc. | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol |
| FR3128874B1 (fr) * | 2021-11-09 | 2025-04-18 | Crossject | Solution pharmaceutique d’hydrocortisone pour dispositif d’injection |
| EP4496575A4 (en) * | 2022-03-21 | 2026-04-01 | Antares Pharma Inc | AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL |
-
2023
- 2023-03-21 EP EP23775847.9A patent/EP4496575A4/en active Pending
- 2023-03-21 WO PCT/US2023/064771 patent/WO2023183807A1/en not_active Ceased
- 2023-03-21 JP JP2024556125A patent/JP2025509955A/ja active Pending
- 2023-03-21 CA CA3246335A patent/CA3246335A1/en active Pending
- 2023-03-24 US US18/189,613 patent/US12102643B2/en active Active
-
2024
- 2024-03-20 US US18/611,251 patent/US12521404B2/en active Active
-
2025
- 2025-12-09 US US19/413,640 patent/US20260091042A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4496575A1 (en) | 2025-01-29 |
| US12102643B2 (en) | 2024-10-01 |
| US20240238311A1 (en) | 2024-07-18 |
| US12521404B2 (en) | 2026-01-13 |
| JP2025509955A (ja) | 2025-04-11 |
| WO2023183807A1 (en) | 2023-09-28 |
| US20230302016A1 (en) | 2023-09-28 |
| US20260091042A1 (en) | 2026-04-02 |
| EP4496575A4 (en) | 2026-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11857555B2 (en) | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | |
| US12083087B2 (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| US20260091042A1 (en) | Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol | |
| JP2009544636A (ja) | メトトレキセート濃厚溶液 | |
| US10206872B2 (en) | Ready-to-administer solution of fentanyl citrate | |
| CN114144170A (zh) | 非质子极性溶剂中的稳定治疗组合物及其制造方法 | |
| US12514837B2 (en) | Stable levothyroxine compositions in aprotic polar solvents | |
| US20230233522A1 (en) | Compositions and methods for treating epilepsy, seizures and other conditions | |
| US20060039869A1 (en) | Intranasal delivery of antipsychotic drugs | |
| US20240148678A1 (en) | Sustained release injectable therapeutic formulations using aprotic polar solvents | |
| CN115645357B (zh) | 一种拉考沙胺口服溶液处方及其制备工艺 | |
| US20230322913A1 (en) | Therapeutic Antibody Formulations | |
| RU2860343C2 (ru) | Водный фармацевтический состав на основе гидрокортизона натрия фосфата и монотиоглицерина | |
| WO2017097432A1 (en) | Preservative free pharmaceutical composition for ophthalmic administration containing dexamethasone | |
| Tannak et al. | Applications of high performance liquid chromatography in the analysis of basic compounds | |
| HK40070081A (en) | Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same | |
| EA050545B1 (ru) | Терапевтические составы антитела |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240919 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240926 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240926 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240926 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250321 |